HomeCompareABT vs NKE

ABT vs NKE: Dividend Comparison 2026

ABT yields 2.36% · NKE yields 3.16%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NKE wins by $1.32M in total portfolio value
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
NKE
NKE
● Live price
3.16%
Share price
$51.24
Annual div
$1.62
5Y div CAGR
66.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.85M
Annual income
$1,337,341.87
Full NKE calculator →

Portfolio growth — ABT vs NKE

📍 NKE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTNKE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + NKE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
NKE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
NKE
Annual income on $10K today (after 15% tax)
$268.74/yr
After 10yr DRIP, annual income (after tax)
$1,136,740.59/yr
At 15% tax rate, NKE beats the other by $857,284.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + NKE for your $10,000?

ABT: 50%NKE: 50%
100% NKE50/50100% ABT
Portfolio after 10yr
$1.19M
Annual income
$833,056.95/yr
Blended yield
69.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NKE right now

ABT
Analyst Ratings
30
Buy
10
Hold
Consensus: Buy
Price Target
$137.67
+35.1% upside vs current
Range: $120.00 — $158.00
Altman Z
4.9
Piotroski
6/9
NKE
Analyst Ratings
1
Strong
42
Buy
23
Hold
4
Sell
Consensus: Buy
Price Target
$75.35
+47.1% upside vs current
Range: $62.00 — $110.00
Altman Z
3.8
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
NKE buys
0
No recent congressional trades found for ABT or NKE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTNKE
Forward yield2.36%3.16%
Annual dividend / share$2.40$1.62
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%66.3%
Portfolio after 10y$533.6K$1.85M
Annual income after 10y$328,772.04$1,337,341.87
Total dividends collected$492.4K$1.78M
Payment frequencyquarterlyquarterly
SectorHealthcareConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$137.67$75.35

Year-by-year: ABT vs NKE ($10,000, DRIP)

YearABT PortfolioABT Income/yrNKE PortfolioNKE Income/yrGap
1← crossover$11,084$384.43$11,226$525.77$142.00NKE
2$12,510$649.94$12,929$917.32$419.00NKE
3$14,505$1,118.82$15,476$1,642.01$971.00NKE
4$17,499$1,978.53$19,614$3,054.78$2.1KNKE
5$22,364$3,640.59$27,004$6,017.26$4.6KNKE
6$31,026$7,096.70$41,770$12,875.77$10.7KNKE
7$48,215$15,016.56$75,648$30,954.02$27.4KNKE
8$87,182$35,592.30$168,071$87,127.77$80.9KNKE
9$191,446$98,161.15$480,693$300,856.83$289.2KNKE
10$533,619$328,772.04$1,851,684$1,337,341.87$1.32MNKE

ABT vs NKE: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

NKEConsumer Discretionary

NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells men's, women's, and kids athletic footwear, apparel, equipment, and accessories worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. In addition, it sells a line of performance equipment and accessories comprising bags, socks, sport balls, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. The company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel. Additionally, it licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. The company sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. The company was formerly known as Blue Ribbon Sports, Inc. and changed its name to NIKE, Inc. in 1971. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.

Full NKE Calculator →
📬

Get this ABT vs NKE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.